iRhythm TechnologiesIRTC
About: iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
Employees: 2,000
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
100% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]
22% more capital invested
Capital invested by funds: $2.54B [Q3] → $3.09B (+$551M) [Q4]
0.03% less ownership
Funds ownership: 109.68% [Q3] → 109.66% (-0.03%) [Q4]
6% less funds holding
Funds holding: 238 [Q3] → 223 (-15) [Q4]
12% less repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 81
24% less first-time investments, than exits
New positions opened: 39 | Existing positions closed: 51
56% less call options, than puts
Call options by funds: $11.4M | Put options by funds: $25.8M
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
Goldman Sachs David Roman 25% 1-year accuracy 5 / 20 met price target | 26%upside $124 | Neutral Maintained | 24 Feb 2025 |
Truist Securities Richard Newitter 46% 1-year accuracy 22 / 48 met price target | 47%upside $145 | Buy Maintained | 21 Feb 2025 |
Wells Fargo Nathan Treybeck 0% 1-year accuracy 0 / 4 met price target | 5%upside $104 | Equal-Weight Maintained | 21 Feb 2025 |
Needham David Saxon 28% 1-year accuracy 18 / 65 met price target | 40%upside $138 | Buy Maintained | 21 Feb 2025 |
Financial journalist opinion
Based on 3 articles about IRTC published over the past 30 days









